S D Baker

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?
    Sharyn D Baker
    J Clin Oncol 24:2412-3. 2006
  2. ncbi request reprint Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Anal Biochem 324:276-84. 2004
  3. ncbi request reprint Relationship of systemic exposure to unbound docetaxel and neutropenia
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Pharmacol Ther 77:43-53. 2005
  4. ncbi request reprint Factors affecting cytochrome P-450 3A activity in cancer patients
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:8341-50. 2004
  5. ncbi request reprint Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
    S D Baker
    Johns Hopkins Oncology Center, Baltimore, MD 21207, USA
    J Clin Oncol 18:915-26. 2000
  6. ncbi request reprint Pharmacology of fluorinated pyrimidines: eniluracil
    S D Baker
    The Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Invest New Drugs 18:373-81. 2000
  7. ncbi request reprint Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:1976-83. 2004
  8. ncbi request reprint Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
    Sharyn D Baker
    Division of Experimental Therapeutics, The Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21237, USA
    J Natl Cancer Inst 94:1883-8. 2002
  9. ncbi request reprint Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence
    E K Rowinsky
    Division of Pharmacology and Experimental Therapeutics, Johns Hopkins Oncology Center, Baltimore, MD, USA
    J Clin Oncol 14:3074-84. 1996
  10. ncbi request reprint A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion
    S O'Reilly
    Johns Hopkins Oncology Center, Baltimore, MD, USA
    Ann Oncol 9:101-4. 1998

Collaborators

Detail Information

Publications71

  1. ncbi request reprint Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?
    Sharyn D Baker
    J Clin Oncol 24:2412-3. 2006
  2. ncbi request reprint Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Anal Biochem 324:276-84. 2004
    ....
  3. ncbi request reprint Relationship of systemic exposure to unbound docetaxel and neutropenia
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Pharmacol Ther 77:43-53. 2005
    ..Our objective was to evaluate the association between exposure to unbound docetaxel and neutropenia in patients with cancer and to identify factors influencing unbound docetaxel clearance...
  4. ncbi request reprint Factors affecting cytochrome P-450 3A activity in cancer patients
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:8341-50. 2004
    ..The purpose is to identify the demographic, physiologic, and inheritable factors that influence CYP3A activity in cancer patients...
  5. ncbi request reprint Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
    S D Baker
    Johns Hopkins Oncology Center, Baltimore, MD 21207, USA
    J Clin Oncol 18:915-26. 2000
    ....
  6. ncbi request reprint Pharmacology of fluorinated pyrimidines: eniluracil
    S D Baker
    The Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Invest New Drugs 18:373-81. 2000
    ..In the presence of eniluracil, oral administration of 5-FU is feasible and variation in 5-FU exposure is reduced, with the anticipation of further reduction in variation as dosing guidelines based on renal function are formulated...
  7. ncbi request reprint Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:1976-83. 2004
    ..The comparative pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) administration schedules were evaluated...
  8. ncbi request reprint Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
    Sharyn D Baker
    Division of Experimental Therapeutics, The Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21237, USA
    J Natl Cancer Inst 94:1883-8. 2002
    ..We conclude that body surface area should not be used to determine starting doses of investigational agents in future phase I studies...
  9. ncbi request reprint Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence
    E K Rowinsky
    Division of Pharmacology and Experimental Therapeutics, Johns Hopkins Oncology Center, Baltimore, MD, USA
    J Clin Oncol 14:3074-84. 1996
    ..The study was designed to evaluate the magnitude of the toxicologic and pharmacologic differences between the two sequences of drug administration...
  10. ncbi request reprint A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion
    S O'Reilly
    Johns Hopkins Oncology Center, Baltimore, MD, USA
    Ann Oncol 9:101-4. 1998
    ..A phase I study was conducted to evaluate the effect of a 24-hour infusion schedule repeated every three weeks, on the therapeutic efficacy of DMP 840...
  11. ncbi request reprint Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
    S D Baker
    The Johns Hopkins Oncology Center, Baltimore, Maryland 21287, USA
    Clin Cancer Res 5:309-17. 1999
    ..The primary elimination pathway for TMZ is by pH-dependent degradation to MTIC and further degradation to AIC. Incomplete recovery of radioactivity may be explained by the incorporation of AIC into nucleic acids...
  12. pmc Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies
    A Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Oncol 19:374-9. 2008
    ..This phase I study tested the feasibility of achieving a troxacitabine steady-state concentration of 20 ng/ml for at least 72 h in patients with solid tumors...
  13. ncbi request reprint A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
    J Gilbert
    Division of Medical Oncology, Department of Oncology, The Johns Hopkins University School of Medicine, 1 M88 Bunting-Blaustein Cancer Research Building, 2650 Orleans Street, Baltimore, MD 21231-1000, USA
    Clin Cancer Res 7:2292-300. 2001
    ..PB may have a role as a cytostatic agent and should be additionally explored in combination with cytotoxics and other novel drugs...
  14. ncbi request reprint Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
    M A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Eur J Cancer 40:1170-8. 2004
    ..Overall, these findings suggest that incorporation of variables in addition to BSA should be considered in routine dosing strategies for doxorubicin and docetaxel...
  15. pmc A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
    ..Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies...
  16. ncbi request reprint Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies
    Michelle A Rudek
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Pharm Biomed Anal 42:253-60. 2006
    ..A 20,000 ng/ml sample that was diluted 1:10 (v/v) with plasma was accurately quantitated. The method has been successfully applied to study the plasma pharmacokinetics of ABT-751 in humans...
  17. ncbi request reprint Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue
    Carlton K K Lee
    Department of Oncology, Johns Hopkins University and Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    Clin Cancer Res 12:2158-65. 2006
    ....
  18. ncbi request reprint In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 11:8503-11. 2005
    ....
  19. ncbi request reprint Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
    Alex Sparreboom
    J Clin Oncol 23:7765-7. 2005
  20. ncbi request reprint Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan
    Nielka P H van Erp
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, The Netherlands
    Clin Cancer Res 11:7800-6. 2005
    ..Here, we investigated whether milk thistle affects the pharmacokinetics of irinotecan, a substrate for CYP3A4 and UGT1A1, in humans...
  21. ncbi request reprint Clinical pharmacokinetics of docetaxel : recent developments
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Pharmacokinet 45:235-52. 2006
    ..Strategies to individualise docetaxel administration schedules based on phenotypic or genotype-dependent differences in CYP3A expression are underway and may ultimately lead to more selective chemotherapeutic use of this agent...
  22. ncbi request reprint Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
    Wells A Messersmith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:1270-5. 2006
    ..Preclinical studies have shown synergy between bortezomib and taxanes. We conducted a phase I study combining bortezomib and docetaxel in refractory solid tumor patients...
  23. ncbi request reprint Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer
    Christopher J Sweeney
    Indiana University Cancer Center, Indianapolis, IN, USA
    Clin Cancer Res 12:536-42. 2006
    ....
  24. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired renal function...
  25. ncbi request reprint A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
    Jill Gilbert
    Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA
    Invest New Drugs 24:499-508. 2006
    ..This was correlated with higher CNDAC Cmax and AUC values. No tumor responses were noted in this heavily pretreated population. However, given the ease of administration and tolerability, further investigation of this agent is warranted...
  26. ncbi request reprint A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 846:1-7. 2007
    ..96. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods (<15%)...
  27. ncbi request reprint Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib
    Nielka P van Erp
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 13:7394-400. 2007
    ..To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib...
  28. doi request reprint Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 14:2102-10. 2008
    ....
  29. ncbi request reprint Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:4707-13. 2007
    ..Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese...
  30. pmc A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Pharm Biomed Anal 43:784-7. 2007
    ..This method was subsequently used to measure concentrations of MS-275 in cancer patients receiving an oral weekly dose of 4 mg/m(2)...
  31. ncbi request reprint Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 13:3731-7. 2007
    ....
  32. pmc Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Cancer Research Building I, Baltimore, MD, USA
    Cancer Chemother Pharmacol 61:423-33. 2008
    ....
  33. ncbi request reprint CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 98:1714-23. 2006
    ..We prospectively assessed the influence of CYP3A activity on gefitinib disposition and toxicity...
  34. pmc Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
    Wells A Messersmith
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Eur J Cancer 43:78-86. 2007
    ..A long half-life and accumulation of BPU and active metabolites were observed, recommending against a continuous administration. Weekly oral BPU therapy should be further tested using an interrupted schedule...
  35. ncbi request reprint Pharmacokinetics and toxicity of weekly docetaxel in older patients
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Clin Cancer Res 12:6100-5. 2006
    ....
  36. pmc Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  37. ncbi request reprint Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Clin Oncol 29:395-8. 2006
    ....
  38. ncbi request reprint Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
    Erin R Gardner
    Clinical Pharmacology Research Core, SAIC Frederick, Frederick, USA
    Clin Pharmacol Ther 80:192-201. 2006
    ....
  39. ncbi request reprint Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies
    Michelle A Rudek
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 1M86, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 828:41-54. 2005
    ..1-20, 0.1-20, 0.5-100, 10-2000, 1-200, and 3-600 ng/mL for BPU, mmBPU, aminoBPU, G280, G308, and G322 in urine, respectively. The method has been successfully applied to study the pharmacokinetics of BPU...
  40. ncbi request reprint Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
    Erin R Lepper
    Science Applications International Corporation Frederick, Maryland, USA
    Clin Cancer Res 11:7398-404. 2005
    ..To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe...
  41. ncbi request reprint Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, Maryland 21231, USA
    Pharmacotherapy 24:16-25. 2004
    ..To determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and potential antitumor activity of temozolomide administered as a single dose every 28 days...
  42. ncbi request reprint Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Oncology (Williston Park) 17:27-31. 2003
    ..However, this combination chemotherapy regimen has an unacceptable rate of febrile neutropenia. This regimen needs to be modified to reduce the incidence of febrile neutropenia...
  43. ncbi request reprint Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins
    Walter J Loos
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 74:364-71. 2003
    ....
  44. ncbi request reprint Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21230 1000, USA
    Clin Cancer Res 9:3589-97. 2003
    ..This Phase I trial examined its toxicity and pharmacokinetics (PKs)...
  45. ncbi request reprint Irinotecan pathway genotype analysis to predict pharmacokinetics
    Ron H J Mathijssen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:3246-53. 2003
    ..The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of putative relevance for irinotecan...
  46. ncbi request reprint Distribution of paclitaxel in plasma and cerebrospinal fluid
    Hans Gelderblom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 14:365-8. 2003
    ..Since the fraction of unbound paclitaxel is different between plasma and CSF, measurement of unbound paclitaxel is required to accurately assess the extent of drug penetration...
  47. ncbi request reprint Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:151-9. 2003
    ..O. Bradley et al., Clin. Cancer Res., 7: 3229-3238, 2001). Here, we examined the role of protein binding as a determinant of the pharmacokinetic behavior of DHA-paclitaxel...
  48. ncbi request reprint Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry
    Alex Sparreboom
    Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, Groene Hilledijk 301, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 773:183-90. 2002
    ..Our current method is approximately 60-100-fold more sensitive than previous assays, and will be used to define Tween 80 disposition in patients receiving Taxotere...
  49. ncbi request reprint Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days
    Karl Belanger
    Centre Hospitalier de l Universite de Montreal CHUM, Hopital Notre Dame, 1560 Sherbrooke Street East, Montreal, Quebec, Canada H2L 4M1 corrected
    J Clin Oncol 20:2567-74. 2002
    ..We conducted a phase I study of troxacitabine given as a 30-minute infusion once every 21 days...
  50. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  51. ncbi request reprint Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 8122 Datapoint Drive, Suite 700, San Antonio, TX 78229, USA
    J Clin Oncol 20:96-109. 2002
    ..To assess the feasibility of administering troxacitabine, a unique L-nucleoside that is not a substrate for deoxycytidine deaminase-mediated catabolism, as a 30-minute intravenous (IV) infusion daily for 5 days...
  52. ncbi request reprint Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 75:448-54. 2004
    ..We investigated the effects of the potent CYP3A4 inhibitor ketoconazole on the pharmacokinetics of docetaxel in patients with cancer...
  53. ncbi request reprint A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Biomed Chromatogr 18:282-7. 2004
    ..The lower limit of quantitation of 0.01 microg/mL allows for successful measurement of plasma concentrations in patients...
  54. ncbi request reprint A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors
    E Claire Dees
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 11:664-71. 2005
  55. ncbi request reprint A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M90, Baltimore, MD 21231, USA
    J Pharm Biomed Anal 37:751-6. 2005
    ..This method is rapid, widely applicable, and suitable for quantifying COL-3 in patient samples enabling further clinical pharmacology characterization of COL-3...
  56. ncbi request reprint Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Anal Biochem 337:143-8. 2005
    ..99. The values for both within-day and between-day precision and accuracy were <15%. This method was used to characterize the plasma pharmacokinetics of bryostatin 1 at doses of 20 microg/m2) to optimize treatment with this agent...
  57. pmc Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study
    Surasak Phuphanich
    The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Neuro Oncol 7:177-82. 2005
    ..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants...
  58. ncbi request reprint Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly
    Albert J ten Tije
    Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 23:1070-7. 2005
    ..To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer...
  59. ncbi request reprint Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry
    Ming Zhao
    Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Steroids 69:721-6. 2004
    ..In conclusion, LC/MS/MS represents a sensitive and accurate means by which to measure four separate steroids within small volume samples of testicular fluid...
  60. ncbi request reprint Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography
    Ming Zhao
    Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M87, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 813:81-8. 2004
    ..This method is 50 times more sensitive than previously published assays and successfully allows studies to characterize the pharmacokinetics and pharmacodynamics of 5AC...
  61. ncbi request reprint Limited cerebrospinal fluid penetration of docetaxel
    Albert J ten Tije
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center Rotterdam, The Netherlands
    Anticancer Drugs 15:715-8. 2004
    ....
  62. ncbi request reprint Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 23:3906-11. 2005
    ..To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor...
  63. pmc Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 26:4172-9. 2008
    ..We conducted a dose selection study with daily rapamycin (sirolimus) in patients with solid tumors employing a modified continuous reassessment method (mCRM) using real-time pharmacodynamic data as primary dose-estimation parameter...
  64. doi request reprint Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
    Shuiying Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale Street, DTRC Room D1034, Mail Stop 314, Memphis, TN 38105, USA
    Mol Cancer Ther 7:1110-20. 2008
    ..Our results highlight the pharmacologic features of sorafenib that may provide it an advantage in the treatment of AML...
  65. ncbi request reprint Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, Room 1M86, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 819:73-80. 2005
    ..This method was subsequently used to measure concentrations of gefitinib in mice following administration of a single dose of 150 mg/kg intraperitoneally and in cancer patients receiving an oral daily dose of 250 mg...
  66. ncbi request reprint Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry
    Ming Zhao
    Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 793:413-20. 2003
    ..Compared to previous assays, this method is simple, specific, and reproducible and will be used to characterize the plasma pharmacokinetics of OSI-774 at doses of 50 to 150 mg to optimize treatment with this agent...
  67. ncbi request reprint Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
    Jing Li
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer Biol Ther 6:432-8. 2007
    ..A functional variant of ABCG2 is associated with greater gefitinib accumulation at steady-state and may be relevant to toxicity and antitumor activity of EGFR TKIs...
  68. ncbi request reprint Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    George Cusatis
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 98:1739-42. 2006
    ..99). The finding suggests that patients with reduced ABCG2 activity due to a common genetic variant are at increased risk for substrate drug-induced diarrhea, with implications for optimizing treatment with such agents...
  69. ncbi request reprint Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches
    Albert J ten Tije
    Clin Pharmacol Ther 74:509-10. 2003
  70. ncbi request reprint Determination of fraction unbound docetaxel using microequilibrium dialysis
    Milin R Acharya
    Clinical Pharmacology Research Core, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Anal Biochem 331:192-4. 2004
  71. pmc Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models
    Yoshinori Kato
    Department of Radiology, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Biol Ther 6:891-7. 2007
    ..The absence of these molecular responses to TMZ treatment in MCF-7 tumors in vivo supports the possibility that the onset of cancer drug resistance is associated with reduced PS, which can decrease delivery of the drug to cancer cells...